It’s World Glaucoma Week, a global initiative of the World Glaucoma Association to raise awareness about glaucoma, the leading cause of irreversible blindness worldwide. Approximately 78 million people have glaucoma globally — affecting 1 in 200 people age 40 and rising to 1 in 8 by age 80. Open-angle glaucoma (OAG), the most common type, develops gradually, often without noticeable symptoms until advanced stages. This chronic, progressive disease makes early detection through regular eye examinations critical, as timely intervention can slow or prevent irreversible vision loss. While current treatments focus primarily on reducing intraocular pressure (IOP), OAG can occur even without elevated eye pressure. ONL Therapeutics is exploring a different approach targeting neuroprotection with a unique and differentiated mechanism of action, potentially addressing vision loss in patients with progressive OAG. Learn more: https://lnkd.in/eCjPucKK #WGW2025 #UnitingForAGlaucomaFreeWorld #GlaucomaWeek #GetTested #GlaucomaInnovation #Neuroprotection #ONL1204
关于我们
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need. ONL’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.
- 网站
-
https://www.onltherapeutics.com
ONL Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Ann Arbor，Michigan
- 类型
- 私人持股
- 创立
- 2011
- 领域
- Ophthalmic Drug Development、Glaucoma、Geographic Atrophy和Retinal Detachment
地点
-
主要
获取路线
524 S Main St
Suite 110
US，Michigan，Ann Arbor，48104
ONL Therapeutics员工
-
Marian Nakada, Ph.D.
Using BIG for GOOD. Making strategic investments for Johnson & Johnson Innovation - JJDC
-
Nichole R.
Dedicated and Focused Administrator with 20+ Years of Experience in Advertising and Tech
-
Connie Chang
Chief Operating Officer at ONL Therapeutics
-
Penny Renee Fleck, MT, MBA
Chief Development Officer at ONL Therapeutics
动态
-
March is Save Your Vision Month! Regular eye exams are your first line of defense against vision loss, but what happens when retinal disease is detected? While early diagnosis is crucial, effective treatment options are equally important. ONL Therapeutics is advancing a pioneering neuroprotective platform aimed at protecting retinal cells from Fas-mediated cell death. This new approach to preserving vision leverages a unique and differentiated mechanism of action (MOA) to inhibit the Fas receptor—a key pathway in retinal cell death. ONL’s lead therapeutic candidate #ONL1204 is a novel, small molecule Fas inhibitor designed to potentially protect vision across a range of retinal diseases and conditions. We're committed to helping patients see the future—bridging early detection with innovative treatment possibilities. Learn more about how the Fas-blocking MOA works: https://lnkd.in/gga8_SNQ #SaveYourVision #VisionHealth #OphthalmicResearch #RetinaInnovation #Neuroprotection #FasMOA?
-
As we wrap up our series for Age-Related Macular Degeneration (AMD) Awareness Month, let’s talk about treatment. There is no cure for AMD – only treatment to slow progression in the advanced stage, aka geographic atrophy (GA), to help preserve vision for as long as possible. Early detection is key! ONL is advancing clinical development of its neuroprotective platform as a potential treatment option for dry AMD/GA. We’re lighting the way to new AMD discoveries! Learn more: https://lnkd.in/eCjPucKK #AMDAwarenessMonth #AMDAwarenessMonth2025 #DryAMD #GeographicAtrophy #Retina #ONL1204
-
-
Last night was electric at the Glaucoma Innovation Summit during the American Glaucoma Society (AGS) 2025 Annual Meeting in Washington, DC! ONL Therapeutics joined leading experts and innovators for an evening of cutting-edge presentations, expert discussions and valuable networking. Dr. Jeffrey Goldberg of the Byers Eye Institute at Stanford University presented our findings on “Fas Inhibition with ONL1204 for the Treatment of Open-Angle Glaucoma.” Special thanks to Dr. Davinder Grover for moderating the engaging session that also featured Astellas, Smartlens and Thea Pharma. The presentations were followed by an insightful expert panel with Drs. Marlene Moster, Emily Schehlein, Peter Chang and Analisa Arosemena. As sponsors of the Glaucoma Innovation Summit, we're proud to support the AGS Foundation's vital research and patient care initiatives. Together, we’re helping patients see the future! #GlaucomaInnovation #RetinaInnovation #AGS2025 #Neuroprotection #ONL1204
-
-
What an incredible night! Our Co-founder and Chief Scientific Officer David Zacks accepted the 2024 Entrepreneur of the Year Award at last night’s New Enterprise Forum Annual Awards Celebration. His pioneering research launched our mission in retinal neuroprotection, leading our team’s work to?help patients see the future. ? Thank you to NEF for this prestigious recognition and to our President and CEO David Esposito for the wonderful introduction with David Maas. ? #BiotechInnovation #Ophthalmology #EntrepreneurOfTheYear #RetinaInnovation #Neuroprotection #ONL1204
-
-
As our series for Age-Related Macular Degeneration (AMD) Awareness Month continues, let’s focus on geographic atrophy (GA), an advanced form of dry AMD that causes irreversible central vision loss. Did you know GA accounts for 20% of all individuals with AMD? This includes approximately 1 million people in the U.S. and 8 million people worldwide. At ONL Therapeutics, we're lighting the way to new AMD discoveries! Learn more about our clinical studies developed to target dry AMD/GA: https://lnkd.in/eCjPucKK #AMDAwarenessMonth #AMDAwarenessMonth2025 #DryAMD #GeographicAtrophy #Retina #ONL1204
-
-
We’re sharing more facts during Age-Related Macular Degeneration (AMD) Awareness Month! Did you know AMD is the leading cause of vision loss in senior populations? 1 in 5 Americans age 65 and older lives with AMD – about 12.2 million people. Of these, approximately 1.3 million have a vision-threatening form of AMD such as geographic atrophy. #AMDAwarenessMonth #AMDAwarenessMonth2025 #DryAMD #GeographicAtrophy #Retina #ONL1204
-
-
Thank you Dr. Baruch D. Kuppermann for presenting our study data at the 2025 Macula Society Annual Meeting. The presentation titled, “AI Analysis of OCT images from a Phase 1b study on ONL1204 Fas Inhibition treatment for GA secondary to AMD” also included AI analysis using RetinAI’s Discovery? technology. Together, we’re lighting the way to new AMD discoveries! #RetinaInnovation #Neuroprotection #DryAMD #GeographicAtrophy #ONL1204
-
-
February is Age-Related Macular Degeneration (AMD) Awareness Month. Throughout February, we're sharing important facts about this progressive eye disease. To start, did you know AMD is considered a neurodegenerative disease (primarily affecting retinal cells in the macula) that causes progressive central vision loss? ONL is advancing clinical development for its pioneering neuroprotective platform across a range of vision-threatening diseases, including geographic atrophy (GA) associated with dry AMD. Learn more: https://lnkd.in/eCjPucKK #AMDAwarenessMonth #AMDAwarenessMonth2025 #DryAMD #GeographicAtrophy #Retina #ONL1204
-
-
Thank you New Enterprise Forum for recognizing our very own David Zacks as NEF Entrepreneur of the Year! The ONL journey was seeded and nurtured early on with key advice, networks and resources through community partners like NEF. We look forward to celebrating with you at next week's forum event.
New Enterprise Forum is excited to announce that registration is now open for our NEF Annual Awards forum event happening on Thursday, February 20, at Ann Arbor SPARK. The evening will kick off at 5:00 p.m. with food, drink and networking, with programming starting at 5:45 p.m.. We will begin with a short presentation from our featured stakeholder of the month, Varnum LLP. Matthew Bower, Partner at Varnum Ann Arbor, will share how Varnum attorneys are there to guide both investors and entrepreneurs every step of the way in helping to create and enhance value. We will then move on to the awards and celebrating entrepreneurs! We will begin by recognizing three 2024 NEF showcase investor presenters as winners in the categories of Best Business Model, Best Technology and Best Presentation. Next, we will present our NEF Entrepreneur of the Year Award to David Zacks, Co-Founder and Chief Scientific Officer of ONL Therapeutics. In September, 2024, ONL closed on a $65 million oversubscribed Series D financing round led by Johnson & Johnson Innovation, backed by a consortium of investors that included Bios Partners, Novartis Venture Fund, Visionary Ventures and ExSight Ventures among others. ONL is pioneering a new approach to preserving vision by developing first-in-class therapeutics to protect and improve the vision of patients with retinal diseases. We are also announcing that Alexa Turnage and Johnnie Turnage, Co-Founders of Black Tech Saturdays (BTS), are being honored with the NEF Startup Community Champion Award this year. While they will not be at the February NEF forum to accept their award due to a conflict, they will be at the March NEF forum to receive the award and we will celebrate with them (again!) then. BTS is an inclusive movement that is not just reshaping tech, but fundamentally changing the trajectory of Black, Brown and underestimated founders in America. What began as a single event has transformed into a nationwide force, drawing nearly 20,000 across six states and generating $30 million in economic impact through venture capital raised, cumulative job salaries, business contracts and company revenues. BTS has attracted new resources, built bridges where barriers once stood and been recognized by the Governor, the Mayor of Detroit and countless leaders as one of the most significant forces in Michigan's innovation economy. The NEF Annual Awards will be an event full of celebration and sharing of journeys! For further information, please visit the NEF website: https://lnkd.in/g3fZ_hcm Please register to attend at: https://lnkd.in/g2c-SN-X